# Pizarra — PT-pseudo_132e0000c0e0 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_132e0000c0e0
Task: 1

Encounter: Urology - outpatient on 01 Feb 2025.
Referrer: Dr. L. Smits (GP).
Type: Re-evaluation - prior negative biopsy.

Clinical data (read-only — values loaded from the record):
  - 57-year-old male
  - PSA: 13.6 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.2 ng/mL²
  - PSA velocity: 0.52 ng/mL/yr
  - Prior PSA: 13.3 ng/mL
  - Prostate volume: 68.0 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Negative (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.83881855 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Chronic kidney disease
  - Problem list / PMHx: Chronic kidney disease
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 13.6 ng/mL. PI-RADS 5. PSAD 0.20. Prostate volume 68 mL. csPCa 0.84.

Vitals: weight 91 kg, height 179 cm, BMI 28.4, BP 107/77 mmHg, HR 64 bpm. Smoking: Ex-smoker (35 pack-yr, quit 2010).

Chief complaint: A clinical review was requested after a previous negative biopsy and a subsequent rise in PSA levels to 13.6 ng/mL.

History: At 57 years of age, this retired greenhouse horticulturalist is married and living with his partner. Adult children visit weekly. Clinical investigation began in late 2023 due to an upward PSA trajectory. Current symptom burden includes moderate lower urinary tract complaints, registering an IPSS score of 12. Nocturia occurs twice per night, accompanied by a somewhat diminished stream, yet hematuria and pelvic discomfort are absent. Chronic kidney disease defines his medical background, currently showing an eGFR below 60 mL/min/1.73m². He maintains a daily twenty-minute walking regimen and abstains from alcohol entirely. Smoking cessation occurred in 2010, concluding a thirty-five pack-year habit. Outside urological concerns, vascular surgery addressed symptomatic varicose veins recently, while dermatology treated actinic keratoses the previous month. His residence sits more than ninety minutes from the hospital, leading him to favor telephone updates when feasible, with his sister listed as next of kin.

Physical examination: DRE: Normal examination. The prostate presents as symmetrically enlarged yet benign, characterized by a smooth, firm consistency without palpable nodules or asymmetry. Vital parameters remain stable, recording a blood pressure of 107/77 mmHg and a heart rate of 64 bpm. General inspection reveals no pallor, jaundice, or peripheral lymphadenopathy.

Patient info: retired greenhouse horticulturalist; Married; Lives with partner; adult children visit weekly.
Next of kin: Sibling (sister).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Walking 20 min/day; IPSS score: 12/35 (moderate LUTS).

Recent other appointments: GP practice nurse — flu vaccination; Vascular surgery — varicose veins consult; Dermatology — actinic keratosis check.
Admin: Lives >90 min from clinic; phone follow-up preferred where clinically safe.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.76 +/- 0.17   (95% CI 0.37-0.98)

Where the uncertainty comes from:
  - aleatoric  dA = 0.14  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.09  (few labelled cases resemble this one)
  - 6.5 effective neighbours out of 10; 5 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {yes}

TIER 'supports': A +/- dA does not cross 0.5, but A +/- 1.96*dA does. There is a direction, not a conclusion. Measured accuracy in this tier: 0.67. Treat it as a weighted vote, not as a decision.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=5.0, bx_ord=1.0, psa=13.6, age=57.0, psad=0.2, dre_ord=0.0, vol=68.0, n_pmhx=1.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
  The statistical recommender only used the structured panel. It could not weigh the patient's history of Chronic Kidney Disease (CKD) and the specific PSA velocity (0.52 ng/mL/yr), which are significant comorbidities/dynamics not explicitly listed in the initial structured variables. It also missed the context provided by the PSA history trend (rise from 13.3 to 13.6 ng/mL) and the full laboratory panel, which might indicate other markers relevant to risk stratification.

WHY THE SUGGESTION COULD BE WRONG
  The prior suggests biopsy (0.76), but the case presents a prior negative biopsy. The high csPCa probability (0.83881855) combined with a PI-RADS 5 is weighed against a normal DRE. The prior's suggestion might be wrong because it fails to adequately weigh the prior negative biopsy status against the current high PSA and PI-RADS 5, potentially over-relying on the high csPCa probability without fully integrating the negative prior result.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
  <laboratory results> -> <the full panel> -> <If markers like creatinine or other renal function indicators suggest a need for caution or alternative management.>
  <PSA history (trend)> -> <the trend beyond the headline value> -> <If the velocity is highly concerning despite the prior negative biopsy.>
  <previous GP / urology consultation notes> -> <notes from late 2023> -> <To understand the clinical context of the initial upward trajectory.>
  <radiology / mpMRI report> -> <full mpMRI prose> -> <To assess the detailed characteristics of the PI-RADS 5 lesion.>

## [4] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
  One block per document you opened. Quote the values and phrases that matter, verbatim and with units. Numbers, lesion descriptions, dates, explicit radiologist or clinician recommendations. Do not paraphrase a number. If a document turned out to be uninformative, say so in one line.

  **radiology / mpMRI report**
  Report Source: Spaarne Gasthuis Radiology | Date: 28 Jan 2025 | Study: Multiparametric MRI of the Prostate
  Clinical indication: Elevated PSA (13.6 ng/mL) and prior negative biopsy.
  FINDINGS:
  Prostate volume registers at 68.0 mL. A 14 mm focal lesion occupies the right anterior mid-gland, appearing markedly hypointense on T2-weighted sequences. Diffusion-weighted imaging confirms restricted diffusion, mirrored by corresponding low signal on the apparent diffusion coefficient map. Dynamic contrast-enhanced sequences demonstrate early, rapid focal enhancement. Pelvic lymph nodes appear unremarkable, and there is no evidence of extraprostatic extension or seminal vesicle invasion.
  IMPRESSION:
  PI-RADS 5 lesion in the right anterior mid-gland measuring approximately 14 mm.
  Prostate volume 68.0 mL yields a PSA density of 0.2 ng/mL/mL.
  csPCa predicted probability 0.83881855

  **psa trend**
  {"date": "Dec 2023", "val": 4.4}, {"date": "Mar 2024", "val": 5.8}, {"date": "Jul 2024", "val": 7.7}, {"date": "Oct 2024", "val": 10.3}, {"date": "Feb 2025", "val": 13.6}

  **previous GP / urology consultation notes**
  {"date": "11 Aug 2023", "author": "Dr. L. Smits (GP)", "text": "A systematic transrectal ultrasound-guided biopsy was performed in July 2023 following an initial PSA reading of 11.6 ng/mL. Histology proved benign, prompting no urological referral and a directive to recheck PSA levels in half a year. During that appointment, the practice nurse also administered a seasonal influenza vaccination."}

  **laboratory results**
  {"name": "PSA", "val": "13.6 ng/mL", "date": "19 Dec 2024", "flag": "H"}, {"name": "Free PSA", "val": "3.72 ng/mL", "date": "19 Dec 2024", "flag": ""}, {"name": "%Free PSA", "val": "27%", "date": "19 Dec 2024", "flag": ""}, {"name": "Haemoglobin", "val": "15.7 g/dL", "date": "19 Dec 2024", "flag": ""}, {"name": "WBC", "val": "6.9 x10^9/L", "date": "19 Dec 2024", "flag": ""}, {"name": "Platelets", "val": "224 x10^9/L", "date": "19 Dec 2024", "flag": ""}, {"name": "Creatinine", "val": "120 umol/L", "date": "19 Dec 2024", "flag": "H"}, {"name": "eGFR", "val": "<60 mL/min/1.73m2", "date": "19 Dec 2024", "flag": "L"}, {"name": "Testosterone", "val": "14.7 nmol/L", "date": "19 Dec 2024", "flag": ""}, {"name": "Alkaline phosphatase", "val": "92 U/L", "date": "19 Dec 2024", "flag": ""}, {"name": "LDH", "val": "148 U/L", "date": "19 Dec 2024", "flag": ""}}

NOT RETRIEVED
  get_family_history: Not called because the retrieval economy suggests it is not necessary for this specific decision point, as per the tool description.

WHAT THE EVIDENCE SUPPORTS
  findings that argue FOR sampling this patient now:
  PI-RADS 5 lesion in the right anterior mid-gland measuring approximately 14 mm
  PSA velocity of 0.52 ng/mL/yr
  csPCa predicted probability 0.83881855
  PSA level of 13.6 ng/mL

  findings that argue AGAINST sampling this patient now:
  Prior biopsy: Negative
  DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)

WHERE THIS LEANS
  The evidence strongly points towards sampling due to the high-risk MRI finding (PI-RADS 5) and the rising PSA velocity, which contradicts the prior negative biopsy. This leans toward a strong recommendation for biopsy.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [5] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [6] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended because the evidence strongly supports sampling due to the high-risk PI-RADS 5 lesion and the rising PSA velocity of 0.52 ng/mL/yr, which contradicts the prior negative biopsy. The decisive factors are the PI-RADS 5 finding and the PSA velocity, which together outweigh the prior negative result. The statistical prior suggested biopsy, and the retrieved evidence confirmed this direction.

Variables that carried weight: bx=decisive, age=noted, dre=noted, psa=decisive, vol=noted, psad=noted, pirads=decisive, comorbidity=important
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
